Phytochemical Analysis and Understanding the Antioxidant and Anticancer Properties of Methanol Extract from Litsea glutinosa: In Vitro and In Vivo Studies

Litsea glutinosa (L. glutinosa) is considered an evidence-based medicinal plant for the treatment of cancer, the leading cause of death worldwide. In our study, the in vitro antioxidant and in vivo anticancer properties of an essential ethno-medicinal plant, L. glutinosa, were examined using non-toxic doses and a phytochemical analysis was executed using gas-chromatography–mass-spectrometry. The in vitro antioxidant study of the L. glutinosa methanolic extract (LGBME) revealed a concentration-dependent antioxidant property. The bark extract showed promising antioxidant effects in the 2,2-diphenyl-1-picryl-hydrazyl (DPPH) assay. The strongest antioxidant activity was demonstrated at the maximum concentration (50 µg/mL). The IC50 values of the LGBME and BHT were 5.51 and 5.01 µg/mL, respectively. At the same concentration, the total antioxidant capacity of the LGBME was 0.161 µg/mL and the ferric reducing antioxidant power assay result of the LGBME was 1.783 µg/mL. In the cytotoxicity study, the LD50 of the LGBME and gallic acid were 24.93 µg/mL and 7.23 µg/mL, respectively. In the in vivo anticancer-activity studies, the LGBME, particularly at a dose of 150 mg/kg/bw, showed significant cell-growth inhibition, decreased tumor weight, increased mean survival rate, and upregulated the reduced hematological parameters in EAC (Ehrlich’s ascites carcinoma)-induced Swiss albino mice. The highest cell-growth inhibition, 85.76%, was observed with the dose of 150 mg/kg/bw. Furthermore, the upregulation of pro-apoptotic genes (p53, Bax) and the downregulation of anti-apoptotic Bcl-2 were observed. In conclusion, LGBME extract has several bioactive phytoconstituents, which confirms the antioxidant and anticancer properties of L. glutinosa.

The results were expressed as mean ± SD (n = 3). The values of a and b were expressed in terms of GAE (gallic-acid equivalent) and CAE (catechin equivalent) (mg of GAE/gm, CAE/gm of dry extract, respectively).

In Vitro Antioxidant Activity of LGBME
The dose-dependent antioxidant activity of the LGBME was observed. The sample showed intense radical-scavenging activity against DPPH (2,2-diphenyl-1-picryl-hydrazyl) in a concentration-dependent manner (IC50 value 5.51) compared with the standard BHT (IC50 value 5.01) ( Figure 2B). The mean absorbances of the LGBME and standard catechin at concentrations of 50 μg/mL were 0.161 ± 0.016 and 0.526 ± 0.001, respectively, measured at 695 nm ( Figure 2A) in a total-antioxidant capacity (TAC) Assay. In addition, the LGBME and catechin demonstrated promising antioxidant activity in a ferric reducing antioxidant power (FRAP) assay in a concentration-dependent manner, when taken at 700 nm. The absorbances of the LGBME and standard catechin at the concentrations mentioned above were 1.783 ± 0.008 and 3.417 ± 0.005, respectively ( Figure 2C).

In Vitro Antioxidant Activity of LGBME
The dose-dependent antioxidant activity of the LGBME was observed. The sample showed intense radical-scavenging activity against DPPH (2,2-diphenyl-1-picryl-hydrazyl) in a concentration-dependent manner (IC 50 value 5.51) compared with the standard BHT (IC 50 value 5.01) ( Figure 2B). The mean absorbances of the LGBME and standard catechin at concentrations of 50 µg/mL were 0.161 ± 0.016 and 0.526 ± 0.001, respectively, measured at 695 nm ( Figure 2A) in a total-antioxidant capacity (TAC) Assay. In addition, the LGBME and catechin demonstrated promising antioxidant activity in a ferric reducing antioxidant power (FRAP) assay in a concentration-dependent manner, when taken at 700 nm. The absorbances of the LGBME and standard catechin at the concentrations mentioned above were 1.783 ± 0.008 and 3.417 ± 0.005, respectively ( Figure 2C). (B) DPPH free-radical-scavenging activity of LGBME and BHT; (C) iron-reducing capacity of LGBME and catechin.

Cytotoxic-Activity Study of LGBME
A brine-shrimp lethality bioassay was used to assess the LGBME's cytotoxic activity against nauplii. The LC 50 value was 24.93 µg/mL, while that of the gallic acid was 7.23 µg/mL (Table 3).

Acute-Toxicity Study of LGBME
The main purpose of the acute-toxicity study was to establish safe doses for the experiment. The activity of the investigational model was observed for the first 3 h and, later, at intervals of 4 h throughout the next 24 h. The foodstuff ingestion exhibited no significant alteration amongst the groups that were monitored. In this study, the mortality rate was null at 250, 500, 1000, and 1500 mg/kg/bw. This indicated that the LD 50 was much higher than 1500 mg/kg/bw.

Anticancer Activity of LGBME
The viability of the EAC cells decreased considerably when they were treated with various doses of LGBME in a concentration-dependent manner ( Figure 3A). Significant EAC cell-growth inhibition (85.76%) with LGBME was observed at the dose of 150 mg/kg.bw/day (i.p.), at doses 50 and 100 mg/kg.bw/day; the values were 60.60% and 68.53%, respectively (p < 0.05), and significant cell-growth inhibition (87.70%) resulted from the use of the standard drug, bleomycin, at 0.3 mg/kg.bw/day, when compared with the control (p < 0.01).
Increased mean survival time (MST) and life span were observed in a dose-dependent manner during the treatment with the LGBME. The MST of the control-mice group was 21.67 ± 0.58, and that of the treatment group was 37.5 ± 1.29 days (p < 0.05) at the dose of 150 mg/kg/day (Table 4) and at doses 50 and 100 mg/kg.bw/day; the values were 29.67 ± 2.65 and 36.33 ± 1.53 days, respectively (p < 0.05). The MST of the standard drug, bleomycin, at 0.3 mg/kg.bw/day, was 40.0 ± 2.08 days (p < 0.001). Significantly increased life span resulted from the treatment with the LGBME dose of 150 mg/kg/day, which was 73.05% compared to the control group; for the standard bleomycin, the value was 82.08%. Data expressed as mean ± SD (n = 6) and significant values at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) by Dunnett's T3 test when compared with the control group.
The effects of the LGBME and bleomycin on the EAC-cell-inoculated mice resulted in dose-dependent tumor-growth inhibition ( Figure 3A). The tumor weights of the control group were elevated by 17.6 g, and in the case of the mice treated with the LGBME at doses of 50, 100, and 150 mg/kg.bw/day, the values were 12.26, 8.86, and 7.47 g, respectively (p < 0.05). The results are shown in Figure 3B. All the groups were compared against the control group using daily weight changes after 20 days of treatment.
The hematological parameters were remarkably decreased in the EAC-cell-bearing control-mouse group compared with the normal-mouse group. However, with the continuation of the LGBME treatment, these parameters (hemoglobin, RBC, and WBC) were reversed towards normal values (Table 5).
The effects of the LGBME and bleomycin on the EAC-cell-inoculated mice resulted in dose-dependent tumor-growth inhibition ( Figure 3A). The tumor weights of the control group were elevated by 17.6 g, and in the case of the mice treated with the LGBME at doses of 50, 100, and 150 mg/kg.bw/day, the values were 12.26, 8.86, and 7.47 g, respectively (p < 0.05). The results are shown in Figure 3B. All the groups were compared against the control group using daily weight changes after 20 days of treatment. (B) effects of LGBME on tumor weight of EAC-bearing mice; results are shown as mean ± SD (n = 6), where significant values are set as * p < 0.05, ** p < 0.01, and *** p < 0.001 for treated (EAC + LGBME) mice compared with EAC-bearing control mice. Table 5. Effects of LGBME on hematological parameters in EAC-bearing mice.

Effects of LGBME on Apoptotic Genes
GAPDH was consistently expressed in both the control and the LGBME-treated groups. The p53 was found to be expressed in the LGBME-treated EAC cells at the dose of 150 mg/kg.bw/day; thereby, the expression of the pro-apoptotic gene Bax was increased in the treated cells compared with the control cells. By contrast, the expression of the anti-apoptotic gene Bcl-2 was decreased in the treated cells compared to the controls. A molecular study of the apoptosis-related genes revealed that the upregulation of p53 and Bax and the downregulation of anti-apoptotic Bcl-2 might be responsible for EAC-cellgrowth inhibition by inducing apoptosis (Figure 4). groups. The p53 was found to be expressed in the LGBME-treated EAC cells at the dose of 150 mg/kg.bw/day; thereby, the expression of the pro-apoptotic gene Bax was increased in the treated cells compared with the control cells. By contrast, the expression of the antiapoptotic gene Bcl-2 was decreased in the treated cells compared to the controls. A molecular study of the apoptosis-related genes revealed that the upregulation of p53 and Bax and the downregulation of anti-apoptotic Bcl-2 might be responsible for EAC-cellgrowth inhibition by inducing apoptosis (Figure 4).

Histopathological Findings of Liver and Kidney Tissues
A histopathologic examination revealed remarkable differences in the liver and kidney cytoarchitectures on the sixth day of cell inoculation in the LGBME-treated mice compared to the control-mouse group ( Figure 5A,B). In the liver sections of the control mice, we found ballooning degeneration, hepatocellular necrosis, higher fatty change, several pyknotic cells, degenerate nuclei, hyperplasia of the Kupffer cells surrounding the central vein, and irregularly shaped central veins, whereas the LGBME (150 mg/kg.bw/day)-

Histopathological Findings of Liver and Kidney Tissues
A histopathologic examination revealed remarkable differences in the liver and kidney cytoarchitectures on the sixth day of cell inoculation in the LGBME-treated mice compared to the control-mouse group ( Figure 5A,B). In the liver sections of the control mice, we found ballooning degeneration, hepatocellular necrosis, higher fatty change, several pyknotic cells, degenerate nuclei, hyperplasia of the Kupffer cells surrounding the central vein, and irregularly shaped central veins, whereas the LGBME (150 mg/kg.bw/day)-treated mice showed restoration of their hepatic architecture with regular-shaped central veins, and hepatocellular necrosis was not found. In addition, pyknotic cells and the Kupffer cells surrounding the central vein were found in fewer quantities than in the control group. A microscopic examination of the kidney sections from both the control and the treated mouse groups showed no significant disturbance in the kidney cytoarchitectures at the same dose ( Figure 5C,D).

Discussion
Traditional herbal medicines have well-recognized uses as complementary and alternative medicines (CAMs) to manage, prevent, or cure a wide range of human diseases, including cancer [21]. Phytochemicals, such as phenolics and flavonoids, are the most copious antioxidants and plant species containing a significant amount of phenolics and flavonoids have been found to be therapeutically efficient in treating cancers [22]. According to previous studies, polyphenolic compounds have been proven to have cytotoxic and

Discussion
Traditional herbal medicines have well-recognized uses as complementary and alternative medicines (CAMs) to manage, prevent, or cure a wide range of human diseases, including cancer [21]. Phytochemicals, such as phenolics and flavonoids, are the most copious antioxidants and plant species containing a significant amount of phenolics and flavonoids have been found to be therapeutically efficient in treating cancers [22]. According to previous studies, polyphenolic compounds have been proven to have cytotoxic and apoptotic effects on various cell lines while protecting normal cells from detrimental effects [23,24]. In our study, the LGBME contained phenolics and flavonoids (Table 1). A previous study suggested that elevated polyphenol (phenolic and flavonoid) content strengthens antioxidant activity [25].
Reactive oxygen species play crucial roles in cancer initiation, and progression and elevated levels were observed in malignant cells compared with their regular counterparts [26,27]. Several anti-oxidative compounds have been shown to protect against experimental carcinogenesis and induce the apoptosis of cancer cells [28]. In this work, LGBME showed intense antioxidant activity in the performed assays ( Figure 2). Furthermore, the strong scavenging capacity of the LGBME with IC 50 (5.51 µg/mL) against the standard BHT was found in the DPPH-scavenging-activity assay, supporting the findings of a previous study [14].
For toxicity determination, brine-shrimp nauplii cytotoxicity assay is an old but standardized and effective method. The LD 50 value of the LGBME was 24.93 ± 1.04 µg/mL (Table 3). From this result, we can say that the plant extract has toxic effects.
For judging plant extracts as potent anticancer agents, the growth inhibition of viable EAC cells, reduction in tumor burden, increase in survival time, and restoration of hematological parameters towards normal levels are considered criteria that need to be fulfilled [21]. These all were satisfied by the LGBME when compared with the results obtained by a simultaneous experiment with a clinically recognized anticancer drug bleomycin, at a dose of 0.3 mg/kg.bw/day) (Figure 3 and Tables 4 and 5). In our experiment, the viable cell count of the EAC cells was decreased to 85.76 % at the highest dose (150 mg/kg.bw/day) of the LGBME. Furthermore, a significant percentage of increased life span (73.05%), high survival time (37.5 days), and remarkably reduced tumor burden were observed compared with the control group at the same dose (Table 4), and the obtained results were statistically significant (p < 0.05). Additionally, the treatment with LGBME brought the hemoglobin content, RBC, and WBC cell count back to near-normal values (Table 5). Furthermore, the presence of some important bioactive compounds, such as δ-Cadinene, 9-Octadecenoic acid methyl ester, di-n-octyl phthalate, etc., was confirmed by the GC-MS analysis ( Table 2 and Figure 1). Among these, δ-Cadinene showed promising apoptotic activity through the growth retardation of ovarian cancer (OVCAR-3) cells via caspase-dependent apoptosis and cell-cycle arrest [34], and the di-n-octyl phthalate showed antitumor activity via the inhibition of tumor-necrosis-factor production [35]. Moreover, a medicinal practitioner of Chittagong hill tracts uses L. glutinosa to treat cancer and cancerous tumors. Therefore, the present anticancer activity studies on L. glutinosa support its ethnomedicinal use in treating cancer and cancerous tumors [15].
According to the acute toxicity study, the LGBME at the dose of 150 mg/kg.bw/day was within the safety margin, as LD 50 should be more than 1500 mg/kg. This was supported by the histopathological examination of the liver and kidney tissues. No toxic changes in the cytoarchitectures of the examined tissues were observed when compared to the control-group mice. Moreover, it was found that 150 mg/kg.bw/day showed the most promising anticancer activity against EAC cells of the three doses. Therefore, the dose 150 mg/kg.bw/day was chosen to evaluate the apoptotic efficiency. The mechanisms of apoptosis through which the LGBME inhibited cell growth and induced apoptosis in the EAC cells were investigated by analyzing the amplification pattern of some well-known apoptosis-related genes. EAC is an undifferentiated ascites carcinoma cell in mice. These cells produce native p53, Bax, and Bcl-2 proteins, as shown by previous studies. In these studies, the downregulation of Bcl-2 protein and the up-regulation of Bax and p53 proteins, induced by Poly-L-Lysine, was also confirmed in EAC cells via Western blot [36].
Proliferation disorder and apoptosis obstacle are well-known characteristics of cancer [37]. Recent studies suggested decreased physiological cell death, i.e., apoptosis, may be responsible for malignancy rather than elevated levels of cell proliferation. As a result, the induction of apoptosis may serve as a new tactic for innovative mechanism-based drug discovery [38,39]. The most studied apoptotic proteins are p53, Bax, and Bcl-2 proteins. They act through the activities of their pro-apoptotic and anti-apoptotic products, thereby serving as indicators of the success or failure of apoptosis. Several studies revealed the high expression of the tumor-suppressor protein p53, followed by the accumulation of the pro-apoptotic protein Bax, which activated the intrinsic pathway of apoptosis [40,41].
Additionally, Bax is considered an early event that sensitizes cells to undergo apoptosis. Some previous studies proposed that Bax upregulation alone can commit a cell to apoptosis [42]. In addition to the action of Bax and the cell cycle, p53 may also suppress Bcl-2; hence, its anti-apoptosis function is impeded [43]. The equilibrium between the pro-apoptotic and anti-apoptotic properties of the Bcl-2 family plays a vital role in actuating cells toward apoptosis [44]. Previous studies have revealed that the upregulation of Bax and the downregulation of Bcl-2 cause susceptibility to the intrinsic pathway of apoptosis [45,46]. In our study, the expression patterns of p53, Bax, and Bcl-2 were studied, and it was found that treatment with LGBME at doses of 150 mg/kg.bw/day induced apoptosis, which was associated with the upregulation of the tumor-suppressor gene p53 and the pro-apoptotic gene Bax and with the downregulation of Bcl-2 expression in EAC cells.

Chemicals and Reagents
In our study, chemicals and reagents used were of analytical grade and purchased from Sigma-Aldrich (St. Louis, MO, USA). In addition, Oligo (dT), dNTPs, and M-MLV reverse transcriptase were collected from Tiangen (Beijing, China).

Preparation of Extract
The fresh and mature stem bark of plant L. glutinosa was collected and authenticated from Bangladesh National Herbarium (BNH) during the autumn season (October 2018) in Mirpur, Dhaka, Bangladesh, with the DACB accession number 48,288. After washing and drying (shed), the bark was ground to a coarse powder and preserved until use at 4 • C. Approximately 0.09 kg powder of bark was soaked in 500 mL of methanol solvent to obtain approximately 0.045 kg of crude methanolic extract, indicated as LGBME. The collection of plant material and all the experimental research and field studies on plants complied with the relevant institutional, national, and international guidelines and legislation.

Determination of Total Phenol and Flavonoid Content
The total phenol and flavonoid [47] content of LGBME were determined spectrophotometrically at 760 nm using Folin-Ciocalteu and aluminum chloride reagent. Total phenolic contents were expressed in terms of gallic-acid equivalent, GAE mg of GA/gm of extract, and the standard curve equation was y = 0.0863x + 0.2372, R 2 = 0.9896. The total flavonoid content was calculated using a calibration curve and the standard curve equation: y = 0.0051x -0.0906, R 2 = 0.9944). Results were expressed as catechin equivalents per gram of dried sample (mg of CA/gm).
The following formula was used to calculate the free-radical-scavenging activity of the sample and standard radical-scavenging rate (%) = [{A 0 -A}/A 0 ] × 100. "A 0 " (blank) denotes the absorbance of DPPH blank solution and "A" denotes the final absorbance of the tested sample after 30 min of incubation.

Total-Antioxidant-Activity Assay
The antioxidant activity of the LGBME was evaluated by the phosphor-molybdenum method [47]. Absorbance was taken at 695 nm. Increased absorbance of the reaction mixture indicated an increased total-antioxidant activity. Standard curve equation: y = 0.0027x + 0.0074, R 2 = 0.9959.

Ferric Reducing Antioxidant Power Assay
The reducing power of LGBME was measured by the ferric reducing method [47]. The amount of Fe 2+ complex was then monitored by measuring the formation of Perl's Prussian blue at 700 nm. A concentration-dependent increase in absorbance indicated an increase in reducing capacity. Standard curve equation: y = 0.0338x + 0.1245, R 2 = 0.9951.

Gas-Chromatography-Mass-Spectrometry (GC-MS) Analysis of LGBME
LGBME was analyzed by GC-MS analysis technique performed by GC (Model CP-3800, Varian, Santa Clara, CA, USA) with MS (model: Varian Saturn-2200) spectrometer equipped with a flame-ionization detector and capillary column with VF-5 ms (30 m × 0.25 mm, 0.25 µm). The instrument was operated using electron-impact-ionization mode under specified conditions (ionization voltage −70 eV, detector temperature 280 • C, and injector temperature 250 • C). Helium, an inert gas, was used as a carrier gas, the flow rate was 1 mL/minute, and the sample injection volume was 1 µL. The initial temperature for the column was 40 • C (1 min), and the final temperature was 310 • C at a gradually increasing rate of 10 • C/minute. Temperature was held constant at 310 • C for 10 min. Chemical compounds were identified by their GC retention time, retention indices relative to n-alkanes, and comparison of their mass spectra with the NIST 2008 (National Institute Standard and Technology 2008) Library data.

Determination of Cytotoxic Activity
The cytotoxicity of LGBME was evaluated using brine-shrimp-lethality bioassay; nauplii were hatched after 48 h in saline water following a published protocol [48]. Various concentrations of LGBME and standard gallic acid (12.5, 25, 50, 100, and 200 µg/mL) were obtained by serial dilution of 1 mg/mL solution. The percentage of mortality was calculated after 24 h of incubation for the concentrations mentioned above, and the LC 50 values were determined using Probit analysis.

Experimental Animal and Ethical Clearance
Swiss albino male mice 4-6 weeks of age, weighing 27 ± 5 g, were taken from the Department of Pharmacy, University of Rajshahi, and used in this study. Mice were housed in a standard room with a 12-h light/dark cycle and controlled temperature and humidity. Animals were also provided with food and water ad libitum. All experiments were performed in accordance with the institutional and national guidelines for laboratory animals, and approved by the Institutional Animal, Medical Ethics, Bio-safety and Biosecurity Committee (IAMEBBC) for Experimentations on Animal, Human, Microbes and Living Natural Sources, Institute of Biological Sciences, University of Rajshahi, Bangladesh (license no: 225/320-IAMEBBC/IBSc). The study was performed in compliance with the ARRIVE guidelines (https://nc3rs.org.uk/arrive-guidelines, accessed on 1 July 2020).

Acute Oral-Toxicity Study
Acute oral-toxicity study was conducted as per the reported method to determine LD 50 [49]. The injected solution was obtained by dissolving LGBME in 2% DMSO in PBS, and intraperitoneal injections were given to Swiss albino mice.

In Vivo Anticancer-Activity Study
In vivo anticancer activity of LGBME was determined by measuring the effect of samples on tumor-cell-growth inhibition, body weight, survival time, and hematological parameters of EAC cell-bearing mice.

Experimental Tumor Model and Preparation of Test Samples
EAC (Ehrlich's ascites carcinoma) cells were used for in vivo anticancer-activity study in our study. First, the initial inoculums of EAC cells were collected from the Indian Institute of Chemical Biology (IICB), Kolkata, India. Next, the EAC cells were cultured and maintained in our laboratory as ascites tumor Swiss albino mice by intraperitoneal injection bi-weekly (1 × 10 6 cells/mouse) taken from a donor mouse with 6-7-day-old ascites tumor.
The plant extract was given through an intraperitoneal injection to three groups of mice (n = 6) at three doses (50, 100, and 150 mg/kg.bw/day), and bleomycin at the dose of 0.3 mg/kg.bw/day was used as standard drug. For this treatment, the crude extract was dissolved in 2% DMSO in PBS; therefore, 100 µL of solution contained the required amount for each dose.

Determination of EAC-Cell-Growth Inhibition
In the cell-growth-inhibition study, at day '0', 1 × 10 6 EAC cells were given to the five groups of Swiss albino mice (n = 6) through a peritoneal injection [49][50][51]. Treatments were started after 24 h of tumor inoculation and continued for five consecutive days. Group I was considered as the control group, receiving 2% DMSO only. On the other hand, Groups II-IV received LGBME at doses of 50, 100, and 150 mg/kg.bw/day, and Group V was treated with standard bleomycin at a dose of 0.3 mg/kg.bw/day. After five days of treatment, mice were sacrificed to collect the cells. The viable cells were identified and counted with Trypan blue and hemocytometer, respectively, under an inverted microscope (XDS-1R, Optika, South Korea). The percentage of cell-growth inhibition was calculated using the following formula: where Tw = mean number of tumor cells of treated groups and Cw = mean number of tumor cells of control groups. For determination of mean survival time (MST) and percentage increase in life span (%ILS) with average tumor weight, experiment was performed according to a published protocol [49]. For judging therapeutic value, 1 × 10 6 EAC cells/mL were inoculated per mouse in five groups (n = 6) on day 0 and after 24 h of tumor inoculation in the peritoneal cavity; treatments continued for 10 days. Daily weight variation up to 20 days was recorded to calculate the tumor growth. In addition, the survival times of both the LGBME-treated and untreated groups were recorded and expressed as mean survival time (MST) in days, and percentage increase in life span (%ILS) was calculated as follows:

Determination of Hematological Parameters
Hematological parameters, such as WBC, RBC, and Hb, were tested by a standard protocol [49]. Counting of total WBC and RBC was performed by using a microscope with a hemocytometer. Hematometer was used to evaluate the percentage of hemoglobin (% Hb). 4.7.6. Evaluation of Apoptotic Effectiveness of LGBME RNA Separation and cDNA Preparation Isolation of RNA was conducted using RNA simple Total RNA Kit (Tiangen, Beijing, China) following the manufacturer's guidelines. Concentration and purity of RNA were evaluated by nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA); 3 µg of isolated RNA were converted to cDNA, and reaction mixture contained 10 mM oligo dT (2 µL), M-MLV reverse transcriptase (1 µL), 10 mM dNTPs (2 µL), 5 × 1st strand buffer (4 µL), and sufficient quantity of dH 2 O to make 20 µL volume.

PCR Amplification of Apoptosis-Related Genes
Briefly, amplification of cDNA was performed by reverse transcriptase-polymerase chain reaction (RT-PCR) using gene-specific oligos [49]. The expression pattern of apoptosisrelated genes, such as p53, BAX, and Bcl-2 was studied by PCR. GAPDH, a housekeeping gene, was used as a control gene. The subsequent specific oligonucleotides (IDT, Singapore) were used.

Histopathologic Evaluation
Livers and kidneys were collected from control (2% DMSO) and treated (dose 150 mg/kg.bw/day) mice after five days of treatment [49], immediately fixed in 10% neutral buffered formalin for at least 24 h, processed by paraffine-embedding technique, stained with hematoxylin and eosin [52], and examined under Motic Advanced system microscope (B, series) with the help of Motic J1.0 software on a Macintosh computer for histopathological changes.

Statistical Analysis
All the analyses were performed in triplicates, and data were expressed as mean ± SD (Standard deviation). Statistical analyses were performed by one-way analysis of variance (ANOVA) followed by Dunnett's T3-test for evaluating the anticancer activity of LGBME using Statistical Package for Social Science (SPSS) statistical software, v16. A p-value < 0.05 was considered to be statistically significant. Levels of significance were tested at 5% (* p-value < 0.05), 1% (** p-value < 0.01), and 0.1% (*** p-value < 0.001), respectively.

Conclusions
Our findings of antioxidant and anticancer activities lend scientific support to the traditional medicinal uses of L. glutinosa for cancer treatment. Several antioxidant and anticancer compounds were discovered in L. glutinosa in our study. Understanding the mechanism of action of these therapeutically active compounds may justify the use of medicinal plants for the prevention and/or treatment of disease. The further isolation and characterization of bioactive compounds could provide a lead compound for cancer treatment. Institutional Review Board Statement: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All experimental protocols completed in our study, including animals, were approved by the Institutional Animal, Medical Ethics, Bio-safety and Bio-security Committee (IAMEBBC) for Experimentations on Animal, Human, Microbes and Living Natural Sources, Institute of Biological Sciences, University of Rajshahi, Bangladesh (license no: 225/320-IAMEBBC/IBSc), according to the International Declaration of Helsinki.